MR
Mylandlahalli Rammohan Ashwini
About Mylandlahalli Rammohan Ashwini
Data last updated:
Mylandlahalli Rammohan Ashwini is a Director at Apitoria Pharma Private Limited (since 2024), Director at Apl Healthcare Limited (since 2024) and Director at Eugia Sez Private Limited (since 2024), and holds 4 more current directorships. The companies operate in Chemicals and Materials, Pharma and Life Sciences. The 7 current companies with reported revenue have a combined latest revenue of ₹11,690 Cr; the largest is Apitoria Pharma Private Limited at ₹6,812 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Apitoria Pharma Private Limited U24298TG2017PTC121342 | Director | 29 Mar 2024 | 2017 | ₹6,812 Cr (FY 2025) | Active |
| Apl Healthcare Limited U24239TG2006PLC052053 | Director | 17 May 2024 | 2006 | ₹4,413 Cr (FY 2025) | Active |
 Eugia Sez Private Limited U24299TG2021PTC148856 | Director | 14 May 2024 | 2021 | ₹383 Cr (FY 2025) | Active |
| Auroactive Pharma Private Limited U24230TG2020PTC138313 | Director | 16 May 2024 | 2020 | ₹37.55 Cr (FY 2025) | Active |
| Auro Peptides Limited U24232TG2012PLC078350 | Director | 30 Oct 2025 | 2012 | ₹23.52 Cr (FY 2025) | Active |
| Auro Vaccines Private Limited U24297TG2021PTC156684 | Director | 17 May 2024 | 2021 | ₹11.82 Cr (FY 2025) | Active |
| Curateq Biologics Private Limited U24110TG2020PTC140190 | Director | 17 May 2024 | 2020 | ₹9.49 Cr (FY 2025) | Active |
Board colleagues of Mylandlahalli Rammohan Ashwini
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Mylandlahalli Rammohan Ashwini
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mylandlahalli Rammohan Ashwini
Mylandlahalli Rammohan Ashwini currently holds 7 directorships: Apitoria Pharma Private Limited (Director, since 29 Mar 2024, revenue ₹6,812 Cr (FY 2025)); Apl Healthcare Limited (Director, since 17 May 2024, revenue ₹4,413 Cr (FY 2025)); Eugia Sez Private Limited (Director, since 14 May 2024, revenue ₹383 Cr (FY 2025)); Auroactive Pharma Private Limited (Director, since 16 May 2024, revenue ₹37.55 Cr (FY 2025)); Auro Peptides Limited (Director, since 30 Oct 2025, revenue ₹23.52 Cr (FY 2025)); and 2 more.
Mylandlahalli Rammohan Ashwini was first appointed on 29 Mar 2024 as Director at Apitoria Pharma Private Limited. The most recent appointment on record is 30 Oct 2025 at Auro Peptides Limited.
The 7 current companies of Mylandlahalli Rammohan Ashwini that report revenue have a combined latest revenue of ₹11,690 Cr: Apitoria Pharma Private Limited ₹6,812 Cr (FY 2025); Apl Healthcare Limited ₹4,413 Cr (FY 2025); Eugia Sez Private Limited ₹383 Cr (FY 2025); Auroactive Pharma Private Limited ₹37.55 Cr (FY 2025); Auro Peptides Limited ₹23.52 Cr (FY 2025); and 2 more.
The current boards of Mylandlahalli Rammohan Ashwini's companies include Brundaban Dash (Apitoria Pharma Private Limited), Nityananda Reddy Kambam (Apitoria Pharma Private Limited), Sanjay Chaturvedi (Apitoria Pharma Private Limited), Sanjay Chaturvedi (Apitoria Pharma Private Limited), Santanu Mukherjee (Apitoria Pharma Private Limited), Santhanam Subramanian (Apitoria Pharma Private Limited), among others.